FDA Acceptance of Supplemental NDA for REVLIMID by Bristol Myers Squibb
The FDA has accepted a supplemental NDA for REVLIMID (lenalidomide) submitted by Bristol Myers Squibb.
Asset / Drug
Drug and asset intelligence for REVLIMID with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.